HLN trades 11.6% below Wall Street's consensus target of $10.20.
Last 12 months price action with 12-month analyst target path
The base valuation assumes HLN achieves its forward estimates and maintains a stable P/E multiple of 21.9x. This scenario reflects the blended consensus of 4 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of November 8, 2026, Haleon plc (HLN) has a Wall Street consensus price target of $10.20, based on estimates from 4 covering analysts. With the stock currently trading at $9.14, this represents a potential upside of +11.6%. The company has a market capitalization of $40.76B.
Analyst price targets range from a low of $10.20 to a high of $10.20, representing a 0% spread in expectations. The median target of $10.20 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 3 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, HLN trades at a trailing P/E of 18.9x and forward P/E of 21.9x. The forward PEG ratio of 2.59 reflects a premium valuation. Analysts expect EPS to grow -40.8% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $12.48, with bear and bull scenarios of $7.86 and $16.44 respectively. Model confidence stands at 41/100, suggesting limited visibility into future performance.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 KVUEKenvue Inc. | $37.1B | $19.31 | $19.50 | +1.0% | Hold | 16.5x | 14 |
 CHDChurch & Dwight Co., Inc. | $25.9B | $109.33 | $109.00 | -0.3% | Buy | 28.9x | 34 |
 PGThe Procter & Gamble Company | $385.2B | $165.40 | $166.78 | +0.8% | Buy | 23.7x | 53 |
 CLColgate-Palmolive Company | $77.3B | $96.56 | $101.00 | +4.6% | Hold | 24.7x | 46 |
 PBHPrestige Consumer Healthcare Inc. | $2.0B | $42.98 | $81.67 | +90.0% | Buy | 9.4x | 17 |
 JNJJohnson & Johnson | $664.9B | $276.22 | $285.31 | +3.3% | Buy | 24.9x | 40 |
 NVSNovartis AG | $309.0B | $162.55 | $149.50 | -8.0% | Hold | 18.3x | 25 |
 GSKGSK plc | $100.8B | $50.33 | $57.95 | +15.1% | Hold | 13.9x | 29 |
 MCKMcKesson Corporation | $126.5B | $1060.84 | $983.13 | -7.3% | Buy | 23.8x | 31 |
 CAHCardinal Health, Inc. | $63.6B | $271.72 | $279.33 | +2.8% | Buy | 21.6x | 33 |
Quick answers to the most common questions about buying HLN stock.
Haleon plc (HLN) has a consensus 12-month price target of $10.2, implying 11.6% upside from $9.14. The 4 analysts covering HLN see moderate appreciation potential.
HLN has a consensus rating of "Buy" based on 4 Wall Street analysts. The rating breakdown is predominantly bullish, with 3 Buy/Strong Buy ratings. The consensus 12-month price target of $10.2 implies 11.6% upside from current levels.
HLN trades at a forward P/E of 21.908x, representing a moderate valuation. With analysts targeting $10.2 (11.6% implied move), the stock appears reasonably valued with upside.
The most bullish Wall Street analyst has a price target of $10.2 for HLN, while the most conservative target is $10.2. The consensus of $10.2 represents the median expectation. Our quantitative valuation model projects a bull case target of $16 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
HLN is lightly followed, with 4 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 3 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month HLN stock forecast based on 4 Wall Street analysts shows a consensus price target of $10.2, with estimates ranging from $10.2 (bear case) to $10.2 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $12, with bear/bull scenarios of $8/$16.
Our quantitative valuation model calculates HLN's fair value at $12 (base case), with a bear case of $8 and bull case of $16. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 41/100.
HLN trades at a forward P/E ratio of 21.9x based on next-twelve-months earnings estimates compared to a trailing P/E of 18.9x. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are optimistic on HLN, with a "Buy" consensus rating and $10.2 price target (11.6% upside). 3 of 4 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
HLN analyst price targets range from $10.2 to $10.2, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $10.2 consensus represents the middle ground. Our model's $8-$16 range provides an independent fundamental perspective.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.